Interviews

Franco Locatelli, MD, PhD, a professor and hematologist from Italy, discusses results from the the phase 2 REACH 5 studies assessing the use of ruxolitinib in pediatric patients with chronic graft versus host disease (cGvHD).

Sydney Townsend, executive director of digital health at Texas Oncology, explains how cancer diagnosis and treatment can impact a patient’s mental well-being and how she assesses a patient’s overall cancer care experience.

Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany, discussed the importance of good communication between health care providers and patients with chronic myeloid leukemia (CML).

Martin Griesshammer, MD, PhD, Johannes Wesling University Clinic, discusses past and current efforts to improve treatment options for patients with polycythemia vera.

In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.

Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, breaks down which subgroup of patients with atopic dermatitis (AD) may benefit the most from emerging therapies, as well as the advantages and disadvantages of these therapies.

Judite Blanc, PhD, University of Miami Miller School of Medicine, discusses how total sleep needs vary among ages and the consequences of these changing hourly totals.

Adam Colborn, JD, director of government relations at the Academy of Managed Care Pharmacy (AMCP), also explains what health systems can do to improve patient access to biosimilars.

Unless all populations are represented adequately in trials, it will be hard to know if a drug works the same in all populations as it does in one specific one, explained Robert Dellavalle, MD, PhD, MSPH, of University of Colorado School of Medicine and Rocky Mountain Regional VA Medical Center.

Andrew Bolibol, a PhD candidate in Harvard University’s Health Policy Program, highlights trends and gaps in health insurance coverage between LGBT and non-LGBT adults.

Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains how education can help with biosimilar adoption and how an updated biosimilar workflow has simplified the prior authorization process.

Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences, discusses results from a recent study for which he was the lead author.

Texas Oncology's Travis Brewer, vice president of payer relations, discusses how collaboration between primary care providers and oncologists can improve population health outcomes by focusing on payer initiatives and strategies.

Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the June 2023 issue of The American Journal of Managed Care® about how employers and their employees are utilizing direct-to-consumer telehealth to reduce the cost of care.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).

In this interview from SLEEP 2023, Andrew McHill, PhD, of Oregon Health and Science University (OHSU), explains the importance of individualizing sleep hygiene recommendations.

Improving access to diabetes technology so that everyone can benefit is a top priority, said David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital.

Biosimilars are starting to make a significant impact in overall drug spending, which is what they are designed to do, said Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic.

Future myasthenia gravis therapies have different mechanisms of action than current treatments, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital, talks about the Timely Interventions for Diabetes Excellence dashboard, increases in continuous glucose monitoring, and more.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, California, discusses the need for novel treatments for patients with diffuse large B-cell lymphoma (DLBCL).

Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions, gave insight into the themes of the upcoming National Alliance Leadership Summits.

Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology, discusses how collaboration between oncologists and primary care physicians (PCPs) can improve patient satisfaction and outcomes.

In this interview from SLEEP 2023, Dayna Johnson, PhD, MPH, MSW, MS, addresses the various pathways through which cardiovascular health is adversely affected by suboptimal sleep health.

Mark Fendrick, MD, and Nicholas Bagley, JD, discuss how the ruling in Braidwood v Becerra could affect availability of preventive care.

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

Martin Griesshammer, MD, PhD, from the Johannes Wesling University Clinic, spoke on the current unmet needs in treating polycythemia vera (PV) and how multistakeholder collaboration can help address them.

More data is emerging on the efficacy of several triplet therapies to treat single-class refractory multiple myeloma (MM), potentially giving patients more therapy options than ever before, according to Tel-Aviv Sourasky Medical Center's Yael Cohen, MD, at the European Hematology Association 2023 Congress.